Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has
accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic …

CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are
increasingly being used to define and stage Alzheimer's disease. These biomarkers can be …

Alzheimer's disease (AD) is the most common cause of dementia and is characterized by
aggregation of amyloid and tau proteins in the brain. Results from genetic studies suggest …

Abstract Phosphorylated Tau181 (pTau181) in CSF and recently in plasma has been
associated with Alzheimer's disease. In the absence of amyloidopathy, individuals with …

Background Amyloid pathology, which is one of the characteristics of Alzheimer's disease
(AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis …

Memory impairment is a result of multiple factors including amyloid-beta (Aβ) accumulation.
Several receptors are mediated for Aβ transport and signaling. Moreover, blood lipids are …

Objective The present work was undertaken to study the genetic contribution to the start of
Alzheimer's disease (AD) with amyloid and tau biomarkers in cognitively intact older …

Abstract Background As Alzheimer's disease (AD) pathology presents decades before
dementia manifests, unbiased biomarker cut-points may more closely reflect presence of …

Background Aggregation of amyloid β into plaques in the brain is one of the earliest
pathological events in Alzheimer's disease (AD). The exact pathophysiology leading to …

Introduction We evaluated for two novel automated biomarker assays how cerebrospinal
fluid (CSF) amyloid beta (Aβ) 1–42‐ratios improved the concordance with amyloid positron …